Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Receivables (2016 - 2026)

Champions Oncology (CSBR) has 15 years of Receivables data on record, last reported at $12.6 million in Q4 2025.

  • For Q4 2025, Receivables rose 9.23% year-over-year to $12.6 million; the TTM value through Oct 2025 reached $12.6 million, up 9.23%, while the annual FY2025 figure was $16.6 million, 7.34% up from the prior year.
  • Receivables reached $12.6 million in Q4 2025 per CSBR's latest filing, down from $14.8 million in the prior quarter.
  • Across five years, Receivables topped out at $21.6 million in Q1 2025 and bottomed at $9.0 million in Q1 2022.
  • Average Receivables over 5 years is $13.2 million, with a median of $12.9 million recorded in 2021.
  • Peak YoY movement for Receivables: surged 102.94% in 2021, then fell 12.12% in 2023.
  • A 5-year view of Receivables shows it stood at $12.6 million in 2021, then grew by 5.38% to $13.3 million in 2022, then fell by 12.12% to $11.7 million in 2023, then fell by 1.8% to $11.5 million in 2024, then rose by 9.23% to $12.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $12.6 million in Q4 2025, $14.8 million in Q3 2025, and $16.6 million in Q2 2025.